Analysts see challenges for Tetra's fragile X syndrome drug

BPN14770, which is being developed by Tetra Discovery Partners for the treatment of fragile X syndrome (FXS), was granted Orphan Drug Designation by the US Food and Drug Administration in April 2018.

However, by the time this drug launches, there could be a handful of new drugs already approved for FXS, according to data and analytics company GlobalData.

Tetra is planning to initiate Phase II trials in adults with FXS and in patients with Alzheimer’s disease in second-quarter 2018 after receiving Investigational New Drug approval in March. The company intends to expand its evaluation of BPN14770 in FXS to pediatric patients later this year.